CO-AEM
AEM today announced the highly anticipated update of the Earth Networks Total Lightning Network® (ENTLN). With significant enhancements to both location accuracy and lightning detection efficiency, the ENTLN now improves the ability for AEM customers to track real-time lightning and provide early warning for severe weather events that could threaten public safety and operational effectiveness.
The enhancements are driven through redesigns of the proprietary ENTLN algorithms and include:
- Exceptional lightning location accuracy now under 100 meters. With enhanced accuracy, those in charge of keeping people and assets safe from severe weather have further precision to make confident decisions in moments that matter.
- Detection efficiency over 95% regionally, with 30-50% more lightning detected worldwide. With increased detection efficiency, the ENTLN improves upon its industry leading reliability.
- 90% cloud-to-ground and in-cloud lightning classification accuracy . For customers who make decisions based on the type of lightning, improved classification enhances the ability to track lightning events relevant to a specific situation.
Lightning data from ENTLN is now available in expanded data formats for seamless consumption into 3rd party applications to investigate weather events, verify strikes and analyze lightning induced damage. These new network capabilities are also accompanied by a redesigned lightning sensor allowing for easier deployments and maintenance in remote environments.
The new lightning offering is now integrated into AEM’s suite of decision support applications including:
- Earth Networks Sferic Products – for safeguarding lives and assets from severe weather including lightning, high winds, and heavy precipitation, the Sferic product line provides over 120 map layers displaying current conditions and forecasting and enables custom alerts to be delivered via email, text, or via push notifications to a companion mobile app.
- OneRain Contrail® – for flood risk management and warning, dam safety, and reservoir gate operations, Contrail delivers lightning information to ensure first responder safety and identify more vigorous convective storms that may exacerbate local flash flooding and high-water conditions.
- FTS360 – for wildfire monitoring and mitigation, FTS360 integrates sensor and station data, camera imagery, and video to provide complete situational awareness of current and potential wildfire events. The lightning data improves response time by providing early detection and verification of potential wildfire ignitions.
“With environmental risks escalating and increased impacts from severe weather events around the world, both the public and private sectors are growing increasingly dependent on real-time weather insights to drive their emergency action plans, keep people safe, and minimize downtime,” said Mark Miller, Chief Commercial Officer, AEM. “We are excited to bring these improvements to our industry-leading lightning detection network and ensure decision makers have access to the most trusted and reliable lightning data on the market.”
“As an early adopter of the new ENTLN, we have been impressed with the increased detection efficiency and location accuracy it has brought to the Australia Total Lightning Network (ATLN),” said Martin Palmer, Managing Director, WeatherZone. “Their data, along with our solutions and insights, provides our customers with the operational intelligence they need to make agile and confident decisions. Earth Networks enables us to provide a comprehensive solution to organisations and businesses across Australia.”
Operating over 1,800 sensors across 100 countries, the Earth Networks Total Lightning Network is the most advanced global lightning network in the world. Its ability to comprehensively monitor both in-cloud and cloud-to-ground lightning enables the creation of faster severe weather alerts, lightning-derived radar alternatives and real-time storm visualization.
The new lightning network capabilities, as well as AEM’s broader set of environmental risk solutions, are on display at the American Meteorological Society (AMS) 102nd Annual Meeting from now until January 27, 2022. To learn more visit AEM at https://aem.eco .
About AEM
AEM is combining global technology leaders to empower communities and organizations to survive and thrive in the face of escalating environment risks. By deploying intelligent sensing networks, operating a secure and scalable data management infrastructure, and delivering high-value analytics through a suite of end-user applications, AEM serves as the essential source for environmental insights. These technologies enable positive outcomes, helping reduce environmental impact and creating a safer world. For more information, visit https://aem.eco .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220124005052/en/
Link:
Social Media:
https://www.facebook.com/Advanced-Environmental-Monitoring-AEM-110375228108391
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
